[{"address1": "8-2, Kyutaromachi 1-chome", "address2": "Chuo-ku", "city": "Osaka", "zip": "541-8564", "country": "Japan", "phone": "81 6 6263 5670", "website": "https://www.ono-pharma.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and Sibylla Biotech for central nervous system disorders. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.", "fullTimeEmployees": 4287, "companyOfficers": [{"maxAge": 1, "name": "Mr. Gyo  Sagara", "age": 67, "title": "CEO & Chairman of the Board", "yearBorn": 1958, "fiscalYear": 2025, "totalPay": 914764, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Toichi  Takino Ph.D.", "age": 57, "title": "President, COO & Representative Director", "yearBorn": 1968, "fiscalYear": 2025, "totalPay": 657084, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Toshihiro  Tsujinaka", "age": 61, "title": "EVP, Executive Director of Corporate Strategy & Planning, HR Division and Representative Director", "yearBorn": 1964, "fiscalYear": 2025, "totalPay": 502476, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Masaki  Ito", "title": "Corporate Executive Officer and Div. Director of Corporate Strategy, Planning & Bus. Management Div.", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Takehiro  Yamada", "title": "Corporate Officer & Head of Risk and Compliance Management Department", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Masayuki  Tanigawa", "title": "Corporate Officer & Head of Business Strategy, License", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hiromu  Habashita Ph.D.", "title": "Corporate Officer & Deputy Executive Director, Discovery & Research", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Shinji  Takai M.D., Ph.D.", "title": "Corporate Officer & Head of Medical Affairs", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Satoshi  Takahagi", "title": "Senior Director of EHS Promotion & Corporate Officer", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Akira  Takada", "title": "Corporate Executive Officer & Executive Director of CMC & Production", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "irWebsite": "http://www.ono.co.jp/eng/investor/index.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 4.91, "open": 4.9, "dayLow": 4.9, "dayHigh": 5.08, "regularMarketPreviousClose": 4.91, "regularMarketOpen": 4.9, "regularMarketDayLow": 4.9, "regularMarketDayHigh": 5.08, "dividendRate": 0.18, "dividendYield": 3.49, "exDividendDate": 1759190400, "payoutRatio": 0.70809996, "fiveYearAvgDividendYield": 3.02, "trailingPE": 21.166666, "forwardPE": 2.2378855, "volume": 763, "regularMarketVolume": 763, "averageVolume": 29075, "averageVolume10days": 17820, "averageDailyVolume10Day": 17820, "bid": 5.08, "ask": 5.12, "bidSize": 4850, "askSize": 700, "marketCap": 7228872704, "fiftyTwoWeekLow": 3.21, "fiftyTwoWeekHigh": 5.11, "allTimeHigh": 21.45, "allTimeLow": 3.21, "fiftyDayAverage": 4.6356, "twoHundredDayAverage": 3.9757, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "sharesOutstanding": 1409863957, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 5e-05, "impliedSharesOutstanding": 1423006516, "bookValue": 10.729756, "priceToBook": 0.4734497, "lastFiscalYearEnd": 1743379200, "nextFiscalYearEnd": 1774915200, "mostRecentQuarter": 1767139200, "trailingEps": 0.24, "forwardEps": 2.27, "lastSplitFactor": "3:1", "lastSplitDate": 1459728000, "52WeekChange": 0.52552557, "SandP52WeekChange": 0.15544534, "lastDividendValue": 0.091, "lastDividendDate": 1743379200, "quoteType": "EQUITY", "currentPrice": 5.08, "recommendationKey": "none", "revenuePerShare": 345.1788, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "JPY", "symbol": "OPHLY", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "marketState": "REGULAR", "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1349184600000, "regularMarketChange": 0.17000008, "regularMarketDayRange": "4.9 - 5.08", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 29075, "dividendDate": 1608076800, "earningsTimestampStart": 1753758000, "earningsTimestampEnd": 1754276400, "earningsCallTimestampStart": 1746701940, "earningsCallTimestampEnd": 1746701940, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.24, "epsForward": 2.27, "exchange": "PNK", "messageBoardId": "finmb_876950", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "regularMarketTime": 1770066000, "fiftyDayAverageChange": 0.44439983, "fiftyDayAverageChangePercent": 0.09586673, "twoHundredDayAverageChange": 1.1043, "twoHundredDayAverageChangePercent": 0.2777624, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "fiftyTwoWeekLowChange": 1.8699999, "fiftyTwoWeekLowChangePercent": 0.58255446, "fiftyTwoWeekRange": "3.21 - 5.11", "fiftyTwoWeekHighChange": -0.03000021, "fiftyTwoWeekHighChangePercent": -0.0058708824, "fiftyTwoWeekChangePercent": 52.55256, "shortName": "Ono Pharmaceutical Co., Ltd.", "longName": "Ono Pharmaceutical Co., Ltd.", "regularMarketChangePercent": 3.4623234, "regularMarketPrice": 5.08, "displayName": "Ono Pharmaceutical", "trailingPegRatio": null, "__fetch_time": "2026-02-03"}]